Nippon Chemiphar and SOM Biotech to Cooperate on New, Orphan Disease Indications for bevantolol (Calvan®)

posted on October 14, 2017

SOM Biotech has determined and validated an entirely new usage for Nippon Chemiphar’s marketed hypertension therapy bevantolol (Calvan®). SOM, after using a proprietary ligand analysis computational algorithm and completing the preclinical assays, determined that bevantolol (coded SOM3355 by SOM) is a highly effective Vesicular Monoamine Transporter Type 2 (VMAT2) inhibitor, a class of compounds that has demonstrated to have success in treating Central Nervous System movement disorders such as Huntington’s Chorea, Tardive Dyskinesia, and Tourette’s syndrome.

Press Release English

Press Release Spanish